ci 988 has been researched along with naloxone in 8 studies
| Studies (ci 988) | Trials (ci 988) | Recent Studies (post-2010) (ci 988) | Studies (naloxone) | Trials (naloxone) | Recent Studies (post-2010) (naloxone) |
|---|---|---|---|---|---|
| 147 | 8 | 14 | 20,134 | 1,257 | 3,321 |
| Protein | Taxonomy | ci 988 (IC50) | naloxone (IC50) |
|---|---|---|---|
| Cytochrome P450 2D6 | Homo sapiens (human) | 2 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.043 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0219 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.0397 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.1896 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.05 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.0795 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.0154 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0089 | |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | 0.0055 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (87.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hökfelt, T; Horwell, DC; Hughes, J; Wiesenfeld-Hallin, Z; Xu, XJ | 3 |
| Blommaert, A; Fournié-Zaluski, MC; Noble, F; Roques, BP | 1 |
| Blommaert, AG; Ducos, B; Fournie-Zaluski, MC; Maldonado, R; Roques, BP; Valverde, O | 1 |
| Hökfelt, T; Hughes, J; Jing-Xia, H; Seiger, Å; Wiesenfeld-Hallin, Z; Xiao-Jun, X | 1 |
| Fournié-Zaluski, MC; Maldonado, R; Roques, BP; Ruiz, F | 1 |
| Boucher, M; Coudoré-Civiale, MA; Eschalier, A; Fournié-Zaluski, MC; Méen, M; Roques, BP | 1 |
8 other study(ies) available for ci 988 and naloxone
| Article | Year |
|---|---|
CI988, a selective antagonist of cholecystokininB receptors, prevents morphine tolerance in the rat.
Topics: Animals; Behavior, Animal; Drug Tolerance; Indoles; Injections, Intraperitoneal; Male; Meglumine; Morphine; Morphine Dependence; Naloxone; Pain Measurement; Rats; Rats, Inbred Strains; Receptors, Cholecystokinin; Substance Withdrawal Syndrome | 1992 |
PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes.
Topics: Analgesics; Animals; Cholecystokinin; Drug Synergism; Female; Galanin; Indoles; Injections, Spinal; Kinetics; Male; Meglumine; Morphine; Naloxone; Nociceptors; Pain; Peptides; Rats; Rats, Inbred Strains; Receptors, Cholecystokinin; Reflex; Sorbitol; Spinal Cord; Time Factors | 1990 |
Studies on the effect of systemic PD134308 (CAM 958) in spinal reflex and pain models with special reference to interaction with morphine and intrathecal galanin.
Topics: Analgesics; Animals; Drug Interactions; Female; Galanin; Indoles; Injections, Intravenous; Injections, Spinal; Male; Meglumine; Morphine; Naloxone; Pain; Peptides; Rats; Rats, Inbred Strains; Receptors, Cholecystokinin; Reflex; Spinal Cord | 1991 |
A selective CCKB receptor antagonist potentiates, mu-, but not delta-opioid receptor-mediated antinociception in the formalin test.
Topics: Analgesics; Animals; Disulfides; Enkephalins; Formaldehyde; Indoles; Male; Meglumine; Mice; Morphine; Naloxone; Naltrexone; Pain Measurement; Phenylalanine; Receptors, Cholecystokinin; Receptors, Opioid, delta; Receptors, Opioid, mu | 1995 |
Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308.
Topics: Analgesics; Animals; Behavior, Animal; Binding, Competitive; Body Temperature; Diprenorphine; Disulfides; Drug Combinations; Drug Synergism; Enkephalins; Indoles; Male; Meglumine; Mice; Morphine; Motor Activity; Naloxone; Phenylalanine; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Substance Withdrawal Syndrome; Weight Loss | 1995 |
Chronic pain-related behaviors in spinally injured rats: evidence for functional alterations of the endogenous cholecystokinin and opioid systems.
Topics: Animals; Anti-Anxiety Agents; Behavior, Animal; Cholecystokinin; Chronic Disease; Diazepam; Endorphins; Female; Indoles; Meglumine; Naloxone; Pain; Pain Measurement; Pain Threshold; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Spinal Cord Injuries; Vocalization, Animal | 1994 |
Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism.
Topics: Analgesics; Animals; Disulfides; Drug Combinations; Enkephalins; Indoles; Male; Meglumine; Methadone; Morphine; Naloxone; Phenylalanine; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Substance Withdrawal Syndrome | 1996 |
Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.
Topics: Aminopeptidases; Animals; Diabetes Mellitus, Experimental; Disulfides; Drug Synergism; Indoles; Male; Meglumine; Naloxone; Naltrexone; Neprilysin; Pain; Pain Measurement; Phenylalanine; Pressure; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Time Factors; Vocalization, Animal; Weight Loss | 2001 |